Inhibitors of HBV replication of Formula (I)

##STR00001##

including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R.sub.1, R.sub.2 and R.sub.4 have the meaning as defined herein.

The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.

Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.

The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I): ##STR00001## Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GPR40 such as diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.

The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I): ##STR00001## Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GPR40 such as diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.

Provided is a compound according to Formula 1 ##STR00001##
wherein X, R, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined herein. The compound of Formula 1 can be useful in a composition and in a method for inducing ferroptosis in a cell.

Provided is a compound according to Formula 1 ##STR00001##
wherein X, R, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined herein. The compound of Formula 1 can be useful in a composition and in a method for inducing ferroptosis in a cell.

Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.

The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6 and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6 to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.

LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein R.sub.b is selected from a single bond, C.sub.4 to C.sub.10 unsubstituted aryl, C.sub.4 to C.sub.10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C.sub.1 to C.sub.10 unsubstituted alkyl, and C.sub.1 to C.sub.10 substituted alkyl; R.sub.c comprises hydrogen, halogen, OH, CO.sub.2CH.sub.3, COOH, CN.sub.2CF.sub.3, CF.sub.3, C.sub.2OH, CONHOH, CCOH, C.sub.4 to C.sub.10 unsubstituted aryl, C.sub.4 to C.sub.10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C.sub.1 to C.sub.10 unsubstituted alkyl, or C.sub.1 to C.sub.10 substituted alkyl; and R.sub.d and R.sub.e are independently hydrogen, OH, COH, COH, COC, COOH, R.sub.f, or are taken together as an unsubstituted or substituted four to eight member nitrogen containing heterocycle ring.